Literature DB >> 8946842

Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.

J Ishizaki1, J R Nevins, B A Sullenger.   

Abstract

The control of cell proliferation is of central importance to the proper development of a multicellular organism, the homeostatic maintenance of tissues, and the ability of certain cell types to respond appropriately to environmental cues. Disruption of normal cell growth control underlies many pathological conditions, including endothelial proliferative disorders in cardiovascular disease as well as the development of malignant tumors. Particularly critical for the control of cell growth is the pathway involving the G1 cyclin-dependent kinases that regulate the Rb family of proteins, which in turn control E2F transcription factor activity. Because E2F is critical for regulation of cell proliferation, we sought to identify and to develop specific inhibitors of E2F function that might also be useful in the control of cellular proliferation. Moreover, because the control of E2F activity appears to be the end result of G1 regulatory cascades, the ability to inhibit E2F may be particularly effective in impeding a wide variety of proliferative events. We have used in vitro selection to isolate several unique RNA species from high complexity RNA libraries that avidly bind to the E2F family of proteins. These RNAs also inhibit the DNA binding capacity of the E2F proteins. We also show that an E2F RNA ligand can block the induction of S phase in quiescent cells stimulated by serum addition. As such, these data demonstrate the critical role for E2F activity in cell proliferation and suggest that such RNA molecules may be effective as therapeutic entities to control cellular proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946842     DOI: 10.1038/nm1296-1386

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  21 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals.

Authors:  R Sears; K Ohtani; J R Nevins
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Targeting a KH-domain protein with RNA decoys.

Authors:  Aleksandr V Makeyev; Dawn L Eastmond; Stephen A Liebhaber
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

4.  Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.

Authors:  Yingmiao Liu; Chien-Tsun Kuan; Jing Mi; Xiuwu Zhang; Bryan M Clary; Darell D Bigner; Bruce A Sullenger
Journal:  Biol Chem       Date:  2009-02       Impact factor: 3.915

5.  Crystal structure of an RNA aptamer bound to thrombin.

Authors:  Stephen B Long; Meredith B Long; Rebekah R White; Bruce A Sullenger
Journal:  RNA       Date:  2008-10-29       Impact factor: 4.942

6.  Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.

Authors:  Y Maeshima; N Kashihara; T Yasuda; H Sugiyama; T Sekikawa; K Okamoto; K Kanao; Y Watanabe; Y S Kanwar; H Makino
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

7.  Collaborative role of E2F transcriptional activity and G1 cyclindependent kinase activity in the induction of S phase.

Authors:  G Leone; J DeGregori; L Jakoi; J G Cook; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

8.  Identification of E2F target genes that are rate limiting for dE2F1-dependent cell proliferation.

Authors:  Anabel Herr; Michelle Longworth; Jun-Yuan Ji; Michael Korenjak; David M Macalpine; Nicholas J Dyson
Journal:  Dev Dyn       Date:  2012-09-17       Impact factor: 3.780

9.  Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

Authors:  Partha Ray; Bruce A Sullenger; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2013-10-23       Impact factor: 5.486

Review 10.  Aptamer-based targeted therapy.

Authors:  Guizhi Zhu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-08-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.